Murata, S. (2022) “The Change in Neutrophil-to-lymphocyte Ratio after Initiation of Nivolumab Monotherapy May be a Strong Marker of Response and Predictor of Prognosis in Advanced Non-small Cell Lung Carcinoma”, Asian Pacific Journal of Cancer Care, 7(1), pp. 191–196. doi: 10.31557/apjcc.2022.7.1.191-196.